Nuclear Diagnostic Products
PharmaLogic (DBA of Nuclear Diagnostic Products) is a private US radiopharmaceutical CDMO/CMO serving pharmaceutical sponsors with CMC capabilities, diagnostic and therapeutic radiopharmaceutical manufacturing, and integrated radiopharmacy distribution.
- Company typePrivate
- Founded1999
- HeadquartersRockaway, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nuclear Diagnostic Products does
PharmaLogic (the operating trade name of Nuclear Diagnostic Products, formally PharmaLogic Holdings Corp.) is a private radiopharmaceutical services company headquartered in Rockaway, New Jersey, founded in 1999 with 11–50 employees. The company operates as a contract development and manufacturing organization (CDMO/CMO) serving pharmaceutical sponsors that require specialized capabilities to advance diagnostic and therapeutic radiopharmaceutical products from clinical development through commercial launch. Its offering is structured around four interconnected service lines: CDMO Services providing CMC (Chemistry, Manufacturing, and Controls) and technical capabilities across the drug lifecycle; CMO Diagnostics for contract manufacturing of diagnostic radiopharmaceuticals; CMO Therapeutics for contract manufacturing of therapeutic radiopharmaceuticals, including novel Actinium-225 (Ac-225) based compounds; and Supply Chain & Radiopharmacy services for distribution and delivery. Underlying technology includes PET (Positron Emission Tomography) radiopharmaceutical manufacturing, Ac-225 production, and integrated radiopharmacy operations, with manufacturing infrastructure including a newly opened PET facility in Atlanta, Georgia (April 2026).
The company's core technology stack is rooted in radiopharmaceutical chemistry, manufacturing controls (CMC), and capital-intensive specialized production infrastructure rather than software or AI/ML. Customer-facing channels are B2B-oriented: a corporate website with service pages and a direct-order portal (including WebOlo ordering), a LinkedIn corporate presence, and press/news distribution for major announcements. Go-to-market is enterprise field sales targeting pharmaceutical companies that lack internal radiopharmaceutical manufacturing infrastructure, with revenue generated through long-term manufacturing contracts (recurring/contract CDMO economics) and managed distribution services for radiopharmacy logistics.
The company's revenue model is B2B contract manufacturing with quote-based pricing (no published pricing); the primary customer segment is "Pharmaceutical Companies (Sponsors)" seeking CMC and technical capabilities, segmented horizontally by therapeutic intent (diagnostic vs. therapeutic). Named customer engagement disclosed in source materials is with Ratio Therapeutics, for which PharmaLogic is manufacturing the Ac-225-based therapeutic RTX-2358 for a Phase 1/2 FAP-targeted radiopharmaceutical study in late-stage aggressive sarcomas. Operating geography is currently described as the Southeast United States, with the Atlanta facility representing its most recently disclosed geographic footprint expansion. No funding rounds, M&A activity, ownership/PE backing, or leadership team details are disclosed in available source material.
Nuclear Diagnostic Products firmographics
Firmographics- Name
- Nuclear Diagnostic Products
- Legal name
- PharmaLogic
- Website
- https://ndprx.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaLogic (DBA of Nuclear Diagnostic Products) is a private US radiopharmaceutical CDMO/CMO serving pharmaceutical sponsors with CMC capabilities, diagnostic and therapeutic radiopharmaceutical manufacturing, and integrated radiopharmacy distribution.
- Ownership category
- akta.pro rank
Nuclear Diagnostic Products industry classification
Industry- Product category
- Radiopharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Nuclear Diagnostic Products is headquartered
LocationHeadquarters
- HQ city
- Rockaway
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nuclear Diagnostic Products business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Infrastructure, Operations, Personnel, Technology or R&D, Supply Chain
Revenue model
- CDMO/CMO Services: Contract development and manufacturing organization services providing pharmaceutical sponsors with CMC and technical capabilities to advance radiopharmaceutical products from clinical development through commercialization. Revenue is generated through long-term manufacturing contracts with pharmaceutical companies.
- Supply Chain & Radiopharmacy Services: Integrated supply chain and radiopharmacy distribution services for diagnostic and therapeutic radiopharmaceuticals.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Nuclear Diagnostic Products product offering
Product offeringCore offering
Nuclear Diagnostic Products (operating as PharmaLogic) provides contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services for diagnostic and therapeutic radiopharmaceuticals. The company delivers CMC and technical capabilities to support pharmaceutical sponsors in advancing radiopharmaceutical drug products from clinical development through commercial launch, complemented by integrated supply chain and radiopharmacy distribution services.
Product overview
PharmaLogic is a radiopharmaceutical services company offering a unified portfolio of four interconnected service lines. The core offering consists of CDMO Services (contract development and manufacturing) which provides CMC and technical capabilities for drug development from clinical through commercial stages. This is complemented by two CMO service lines—CMO Diagnostics for diagnostic radiopharmaceutical manufacturing and CMO Therapeutics for therapeutic radiopharmaceutical manufacturing. Additionally, Supply Chain & Radiopharmacy services ensure efficient distribution and delivery of products. Together, these services enable pharmaceutical companies to advance products from clinical development to commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO Services Contract development and manufacturing organization services providing CMC (Chemistry, Manufacturing, and Controls) and technical capabilities to support pharmaceutical sponsors in advancing radiopharmaceutical drug development from clinical development through commercial launch.
- CMO Diagnostics Contract manufacturing organization services specializing in diagnostic radiopharmaceuticals for imaging applications, including PET radiopharmaceutical manufacturing.
- CMO Therapeutics Contract manufacturing organization services specializing in therapeutic radiopharmaceuticals for treatment applications, including novel Actinium-225 (Ac-225) based therapeutics.
- Supply Chain & Radiopharmacy Comprehensive supply chain management and radiopharmacy services enabling efficient distribution and delivery of radiopharmaceutical products to end users.
Quantifiable outcome
- First cohort dosing successfully completed for Ratio Therapeutics Phase 1/2 study
Companies that use Nuclear Diagnostic Products
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Nuclear Diagnostic Products technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nuclear Diagnostic Products partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ratio TherapeuticscorePharmaLogic and Ratio Therapeutics expanded their manufacturing collaboration to support clinical development of Ac-225 RTX-2358. Additionally, PharmaLogic announced successful supply of the first cohort dosing for Ratio Therapeutics' Phase 1/2 study of a novel FAP-targeted radiopharmaceutical in late-stage aggressive sarcomas (December 2025). The partnership involves manufacturing of Actinium-225 based therapeutic radiopharmaceuticals.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
Nuclear Diagnostic Products competitors and assessment
Company assessmentDirect peers
- IBA Radiopharma Solutions: Provides radiopharma production facilities, isotope supply, and contract manufacturing services, competing for the same CDMO/CMO sponsor business for both diagnostic and therapeutic radiopharmaceuticals.
- PETNET Solutions (Siemens Healthineers): Largest US PET radiopharmaceutical manufacturing and distribution network, directly competing with PharmaLogic's CMO Diagnostics and Supply Chain & Radiopharmacy offerings for sponsor and hospital customers.
- Cardinal Health Nuclear & Precision Health Solutions: Operates the largest radiopharmacy network in the US, directly comparable to PharmaLogic's radiopharmacy distribution and supply chain services for diagnostic radiopharmaceuticals.
- Curium Pharma: Global nuclear medicine company providing diagnostic and therapeutic radiopharmaceutical manufacturing, closely overlapping with PharmaLogic's CDMO/CMO Diagnostics and CMO Therapeutics services.
- ABX Advanced Biochemical Compounds: Specialized CDMO for radiopharmaceutical precursors and finished doses; comparable in scale and niche focus to PharmaLogic's CDMO and CMO Diagnostics offerings.
- ITM Isotope Technologies Munich: CDMO specializing in therapeutic and diagnostic radioisotopes including lutetium-177 and actinium-225, directly comparable to PharmaLogic's emerging Ac-225 therapeutic manufacturing focus.
Broad incumbents
- GE HealthCare (Radiopharmaceuticals): Major incumbent across imaging and radiopharma (including SOFIE Biosciences), with broad manufacturing and distribution capabilities that overlap with PharmaLogic's diagnostic and therapeutic CMO offerings.
- Bayer (Radiology / Curium JV): Through its stake in Curium and broader radiology franchise, Bayer competes for the same sponsor and hospital customers for diagnostic and therapeutic radiopharmaceutical manufacturing.
- Lantheus Holdings: Established diagnostic radiopharmaceutical company with proprietary products (e.g., Pylarify, Definity) and emerging therapeutic programs; broader portfolio than PharmaLogic but operates in the same radiopharma value chain.
Emerging players
- Telix Pharmaceuticals: Theranostic radiopharmaceutical sponsor with growing commercial and clinical assets (e.g., Illuccix); serves as both a potential customer for CDMOs like PharmaLogic and an emerging competitor for Ac-225/Lu-177 programs.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Nuclear Diagnostic Products social profiles
Digital presenceNuclear Diagnostic Products financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuclear Diagnostic Products leadership team
Management profileNumber of profiles
Nuclear Diagnostic Products funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuclear Diagnostic Products M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuclear Diagnostic Products
What does Nuclear Diagnostic Products do?
Nuclear Diagnostic Products (operating as PharmaLogic) provides contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services for diagnostic and therapeutic radiopharmaceuticals. The company delivers CMC and technical capabilities to support pharmaceutical sponsors in advancing radiopharmaceutical drug products from clinical development through commercial launch, complemented by integrated supply chain and radiopharmacy distribution services.
Is Nuclear Diagnostic Products a public or private company?
Nuclear Diagnostic Products is a private company. It is classified as unknown and is currently operating.
When was Nuclear Diagnostic Products founded?
Nuclear Diagnostic Products was founded in 1999. It employs 11 to 50 people.
Where is Nuclear Diagnostic Products based?
Nuclear Diagnostic Products is headquartered in Rockaway, United States, in the North America region.
How does Nuclear Diagnostic Products make money?
Two revenue lines are on record. CDMO/CMO Services are the primary driver. The others are supply Chain & Radiopharmacy Services.
Who are Nuclear Diagnostic Products's main competitors?
Direct peers on record are IBA Radiopharma Solutions, PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health Solutions, Curium Pharma, ABX Advanced Biochemical Compounds and ITM Isotope Technologies Munich. Broad incumbents are GE HealthCare (Radiopharmaceuticals), Bayer (Radiology / Curium JV) and Lantheus Holdings. Telix Pharmaceuticals is listed as an emerging player.
Does Nuclear Diagnostic Products have an API?
No public API is recorded for Nuclear Diagnostic Products.
What industry is Nuclear Diagnostic Products in?
Nuclear Diagnostic Products's product category is Radiopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAIAGAE, Radiopharmacy Compounding & Dispensing (Hospital/Commercial). Its NAICS code is 325412 and its SIC code is 2835.